Cesca Therapeutics Inc (NASDAQ:KOOL) announced today it has received Notice of Allowance for U.S. patent application, protecting the company’s proprietary method for separating rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources, while maintaining the viability of the cells under asceptic conditions. This advanced cell separation technology, known as Buoyancy-Activated Cell Separation, or BACS, is key to the ongoing development of Cesca’s CAR-TXpress platform. Moreover, this will be Cesca’s second patent in a series relating to its X-BACS technology.
Investors reacted positively to the news, bidding up Cesca stock nearly 35% to $4.83 as of 1:02PM EDT.
Cesca CEO commented, “This Notice of Allowance further strengthens our intellectual property position as we advance development of our novel CAR-TXpress™ solution for the automated manufacture of CAR-T cells […] CAR-T represents the future of cancer treatment, yet we believe speed, cost and consistency will likely emerge as significant industry challenges. With the X-BACS technology embedded in CAR-TXpress, manufacturers will be able to improve the yield and consistency of CAR-T cells in less time and at a lower cost. We look forward to partnering with some of the most innovative biopharmaceutical companies in the field to enhance the commercial viability of these ground-breaking treatments.”
Philip Coelho, co-inventor of the allowed patent, said, “We are pleased that the USPTO continues to recognize the unique attributes of the X-BACS technology […] In clinical trials, CAR-T immunotherapies continue to show unprecedented results where currently available treatments have failed, but the delivery of CAR-T represents a significant departure from legacy biopharmaceutical business models. We are eager to leverage X-BACS to make these expensive and time-consuming treatments more broadly available to patients in need.”
The X-BACS technology employs microscopic bubbles to isolate a specific cell type from a complex mixture of cells, such as blood. These microbubbles bear antibodies on their surface, enabling them to bind specifically to a single desired target cell type. When coated with microbubbles, the target cells float to the top of the host liquid, while non-target cells sink to the bottom – a process that can be accelerated by centrifugation. Subsequent collection of the floating target cell layer and release of the cells from their microbubbles provides a highly-purified preparation of just the cells of interest, with high recovery efficiency while retaining cell viability.
Cesca engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It operates through the Clinical Development Division and Device Division business segments. The Clinical Development Division segment involves in developing autologous stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology, and orthopedic markets. The Device Division segment includes development and commercialization of automated technologies for cell-based therapeutics and bio-processing.